细胞周期蛋白依赖性激酶4/6抑制剂相关血栓栓塞:对当前证据的批判性评价
本文综述CDK4/6抑制剂在激素受体阳性乳腺癌中临床试验和真实世界研究的血栓栓塞风险证据,比较帕博西利、瑞博西利和阿贝西利三种药物的静脉和动脉血栓风险,指出真实世界中血栓发生率高于早期试验,预防性抗凝的作用尚不明确。
要点
- CDK4/6抑制剂相关血栓栓塞尤其静脉血栓栓塞是新兴临床关注点。
- 真实世界研究中血栓发生率高于早期临床试验报告的发生率。
- 接受CDK4/6抑制剂女性中预防性抗凝的作用仍未知。
核心结论
- CDK4/6抑制剂治疗与血栓栓塞风险相关,真实世界中静脉血栓栓塞发生率高于早期试验,预防性抗凝的作用尚不明确,未来需仔细研究血栓预防的风险与获益。
研究设计与样本
- 本文为综述,汇总CDK4/6抑制剂在临床试验和真实世界研究中的血栓栓塞风险证据。
主要发现
- 静脉血栓栓塞最初在早期试验中作为关注的不良反应出现,近期真实世界研究显示血栓发生率更高。
- 综述比较了帕博西利、瑞博西利和阿贝西利三种获批用于乳腺癌的药物各自的静脉和动脉血栓栓塞风险。
临床怎么用
- 作者认为,接受CDK4/6抑制剂女性中预防性抗凝的作用仍未知,未来需仔细研究血栓预防的风险与获益以改善结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors are an essential treatment modality for hormone receptor-positive breast cancer. As the rates of breast cancer continue to rise globally and the indications for CDK 4/6 inhibitors now extend beyond metastatic disease, more patients than ever are receiving these agents. Thrombosis is an emerging clinical concern with this class of agents, particularly venous thromboembolism. Although venous thromboembolism initially emerged as an adverse effect of interest in early trials, more recent studies have demonstrated even higher incidences of thrombosis in real-world clinical practice. In this review, we summarize the evidence to date that has informed the thrombosis risk for these agents both in clinical trials and real-world studies. We review data describing the venous and arterial thromboembolic risks in clinical trials of CDK 4/6 inhibitors as well as the now rather extensive real-world evidence available, including a comparison of risk for each of the 3 agents approved for use in breast cancer: palcociclib, ribociclib, and abemaciclib. As the role of prophylactic anticoagulation continues to remain unknown in women receiving CDK 4/6 inhibitors, future efforts directed at carefully investigating the risks and benefits of thromboprophylaxis may lead to improved outcomes in these patients.
引用
- Watson NW, Shatzel JJ, Al-Samkari H, et al. Cyclin-dependent kinase 4/6 inhibitor-associated thromboembolism: a critical evaluation of the current evidence. J Thromb Haemost. 2022. PMID: 36696184. doi:10.1016/j.jtha.2022.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。